Asia Pacific RNA-based Therapeutics Market Size and Forecast 2032

Asia Pacific RNA-based Therapeutics Market Overview:

The Asia Pacific RNA-based Therapeutics Market size was valued at USD 1,025.76 MN in 2021 and reached USD 1,749.49 MN in 2025. It is anticipated to reach USD 4,685.07 MN by 2032, growing at a CAGR of 12.57% during the forecast period.

Asia Pacific RNA-based Therapeutics Market Insights

• Market growth is supported by mRNA vaccine adoption, RNA interference drug commercialization, RNA antisense innovation, rare genetic disease treatment demand and expanding clinical research infrastructure.
• Vaccines hold a strong position because mRNA vaccines remain relevant for COVID-19, RSV, influenza pipeline development and broader infectious disease preparedness.
• RNA interference is gaining momentum as approved RNAi therapies expand commercial performance and create stronger confidence in gene-silencing platforms.
• Hospitals remain the leading end-use segment because RNA-based therapeutics often require specialist prescribing, cold-chain handling, clinical monitoring and reimbursement documentation.

Asia Pacific RNA-based Therapeutics Market segment Insights

By product

By product, Vaccines held the strongest position in 2025 because mRNA vaccine platforms gained broad acceptance through COVID-19 prevention and are expanding into RSV, influenza and other infectious disease areas. Vaccines benefit from public-sector procurement, seasonal update models, pandemic preparedness and rapid antigen redesign capability. Drugs are gaining momentum as RNA interference and RNA antisense therapies move deeper into rare genetic disease, cardiometabolic disease, neurology and specialty medicine. Drug growth will depend on target validation, delivery technology, safety profile, payer access and physician confidence. Vaccines will remain important, but Drugs are expected to gain higher long-term value as more RNA-based therapeutics secure approvals.

By type

By type, RNA interference held a strong position in 2025 because RNAi medicines have demonstrated commercial relevance across rare disease and cardiometabolic treatment pathways. RNA interference drugs can silence disease-causing genes and support durable therapeutic effects through targeted delivery. RNA antisense remains a major technology category due to its use in rare genetic disorders, neurology, cardiometabolic disease and protein modulation. Antisense oligonucleotides support flexible drug design and can target RNA transcripts that are difficult to address through conventional small molecules. Growth across both types will depend on delivery systems, dosing convenience, safety monitoring, clinical evidence and disease-specific regulatory pathways.

By indication

By indication, Infectious Diseases held the strongest position in 2025 because RNA vaccine platforms remain highly relevant for COVID-19 updates, RSV prevention, influenza development and emerging pathogen preparedness. Rare Genetics Disease is gaining strong value because RNA interference and RNA antisense therapies can address genetically defined disease mechanisms. This segment benefits from orphan drug pathways, specialist diagnosis and high unmet need. Others include cardiometabolic diseases, neurology, oncology, immunology and liver-targeted conditions. Indication growth will depend on diagnosis rates, genetic testing, clinical trial access, reimbursement policy and launch readiness across Japan, China, South Korea, Australia, India and Southeast Asia.

By end use

By end use, Hospital held the strongest position in 2025 because RNA-based therapeutics frequently require physician-led diagnosis, monitoring, parenteral delivery, adverse event management and payer documentation. Specialty Centers are gaining demand as rare disease clinics, genetic medicine centers, infectious disease centers and specialty infusion networks expand. Research Institutes remain important because RNA therapeutics depend on platform innovation, target discovery, delivery systems, preclinical validation and translational research. Hospital adoption will remain strongest for approved therapies, while Research Institutes will drive pipeline expansion. Specialty Centers will grow as care shifts toward targeted outpatient treatment and rare disease management.

Key Market Drivers

mRNA vaccine adoption and infectious disease preparedness

mRNA vaccine adoption and infectious disease preparedness represent major growth drivers for the Asia Pacific RNA-based Therapeutics Market. RNA vaccines remain relevant because infectious disease programs require rapid variant adaptation, scalable manufacturing and recurring seasonal updates.

WHO’s Western Pacific Region describes the newest mRNA vaccines as part of modern immunization progress and says its 2021-2030 immunization framework aims to expand the scope of immunization, maximize vaccine benefits and accelerate control of vaccine-preventable diseases. Moderna Japan also received marketing authorization in May 2025 for mRESVIA, an RSV mRNA vaccine for adults aged 60 and older, based on a Phase 3 trial that included about 37,000 adults across 22 countries, including Japan. This driver supports Vaccines, Infectious Diseases, Hospitals and Specialty Centers.

Regulatory and commercial momentum for updated RNA vaccines

Regulatory and commercial momentum for updated RNA vaccines supports sustained regional demand. Japan and Australia continue to review and approve updated RNA vaccine products for respiratory infection prevention, which supports platform continuity beyond the initial pandemic cycle.

Pfizer and BioNTech received Japan manufacturing and marketing approval in August 2025 for LP.8.1-adapted Comirnaty COVID-19 vaccine formulations across age groups, including adults, children and young children. Australia’s Therapeutic Goods Administration also approved Moderna’s mNEXSPIKE XBB.1.5 COVID-19 mRNA vaccine for active immunization in individuals aged 12 years and older. This activity supports Vaccines, Infectious Diseases and hospital-led or public-sector vaccination pathways.

RNA interference commercialization

RNA interference commercialization is strengthening confidence in RNA-based drugs. RNAi therapies are expanding beyond early niche use and are generating significant product revenue, which supports investment in platform research, delivery systems and regional launches.

Alnylam reported that AMVUTTRA and ONPATTRO generated full-year 2025 revenues of USD 2.314 billion and USD 173 million, respectively, representing 103% total TTR growth compared with full-year 2024. Alnylam also described RNA interference as a new class of gene-silencing medicines capable of transforming human health. This driver supports RNA interference, Drugs, Rare Genetics Disease, Hospitals and Specialty Centers.

RNA antisense innovation in rare disease care

RNA antisense innovation supports market growth as antisense therapies move into rare genetic disease, neurology and cardiometabolic indications. These therapies can modulate RNA expression and address disease pathways that are difficult for conventional drugs.

Ionis reported that WAINUA generated USD 212 million in sales in 2025, producing USD 49 million in royalty revenue for the company. Sarepta also reported full-year 2025 PMO net product revenue of USD 965.6 million, reflecting continued commercial relevance for exon-skipping RNA therapies in rare disease care. This driver supports RNA antisense, Drugs, Rare Genetics Disease and specialty treatment settings.

Key Trends and Opportunities

RNA drug pipelines shift beyond vaccines

RNA drug pipelines are shifting beyond vaccines as developers expand RNA interference, antisense, circular RNA and mRNA therapeutics into rare disease, cardiometabolic disease, neurology and oncology-adjacent applications. Moderna’s 2025 Form 10-K said the company continues to build commercial subsidiaries in key markets across North America, Europe and the Asia-Pacific region, while its vaccine and broader mRNA platform strategy remains active. This trend supports Drugs, RNA interference, RNA antisense and Research Institutes. Growth will favor companies that can solve delivery challenges, demonstrate durable clinical benefit and secure specialty reimbursement.

Rare genetic disease treatment creates premium opportunities

Rare genetic disease treatment creates premium opportunities because RNA-based therapeutics can directly target inherited disease mechanisms. RNA interference and RNA antisense platforms can reduce disease-causing proteins, alter splicing or modify transcript behavior. Specialty Centers and Hospitals will remain important because rare disease patients require diagnosis, genetic testing, monitoring and long-term treatment coordination. This trend supports Rare Genetics Disease, Drugs, RNA interference and RNA antisense. Adoption will depend on local genetic testing access, orphan drug policy, pricing, registries and patient assistance programs.

Research institutes drive platform innovation

Research Institutes are becoming more important as RNA-based therapeutics require advances in delivery chemistry, lipid nanoparticles, GalNAc conjugates, RNA stability, immune modulation and manufacturing. GSK and CureVac have worked together since 2020 on mRNA vaccines for infectious diseases, and GSK restructured the collaboration into a licensing agreement for mRNA vaccine candidates in 2024. Merck and Orna Therapeutics also formed a collaboration to advance circular RNA technology across vaccine and therapeutic programs. These activities support Research Institutes, Vaccines, Drugs and future RNA platform expansion across Asia Pacific.

Key Market Challenges

Delivery and stability limitations

Delivery and stability limitations remain key challenges for the Asia Pacific RNA-based Therapeutics Market. RNA medicines require protection from degradation and efficient delivery to target cells or tissues. Vaccines often depend on lipid nanoparticle systems and cold-chain management, while RNA interference and antisense drugs need tissue-specific uptake, repeat dosing and careful safety monitoring. Delivery limitations can restrict indication expansion beyond liver-targeted diseases and injectable vaccines. Companies must improve formulation stability, targeting technology, storage conditions and tolerability to support broader adoption.

High therapy cost and reimbursement barriers

High therapy cost and reimbursement barriers limit access to RNA-based drugs. RNA interference and antisense products often serve specialty or rare disease populations and may carry premium prices. Hospitals and payers require strong evidence of clinical benefit, durability and long-term safety before adoption. Emerging Asia Pacific markets may face delayed access due to affordability constraints, limited insurance coverage and fragmented reimbursement pathways. Vaccines benefit from public procurement, but specialty RNA drugs depend more on country-specific reimbursement and patient support programs. Pricing strategy will remain critical through 2032.

Regulatory and manufacturing complexity

Regulatory and manufacturing complexity can slow market growth. RNA-based therapeutics require robust chemistry, manufacturing and controls documentation, impurity testing, delivery-system validation and post-market monitoring. Products may also require variant updates, batch consistency controls and cold-chain verification. Country-level regulatory variation across Asia Pacific can extend launch timelines and increase compliance cost. Manufacturers need scalable production, specialized raw materials, quality systems and regional regulatory expertise. Research Institutes and companies must also address intellectual property complexity across delivery systems and RNA chemistry.

Regional Analysis

China

China represents a major opportunity within the Asia Pacific RNA-based Therapeutics Market due to its large patient population, expanding biotech industry, growing clinical trial base and government interest in advanced therapies. Vaccines and Drugs both offer growth opportunities, with infectious disease preparedness, rare genetic disease care and oncology-adjacent research supporting pipeline activity. Hospitals dominate commercial use, while Research Institutes drive translational work in delivery technologies, synthetic biology and gene-silencing platforms. Local biotech companies are expected to increase competition in RNA interference, mRNA vaccines and nucleic acid delivery. Growth will depend on regulatory approval speed, reimbursement, manufacturing scale and clinical evidence.

Japan

Japan supports strong RNA-based therapeutics demand due to advanced regulation, mature hospitals, specialist care and early adoption of innovative medicines. The country continues to approve updated mRNA vaccines and has become an important launch market for respiratory RNA vaccine products. Moderna Japan’s 2025 approval of mRESVIA and Pfizer-BioNTech’s 2025 approval for LP.8.1-adapted Comirnaty formulations reinforce Japan’s role in RNA vaccine adoption. Specialty Centers and Hospitals are expected to support RNAi and antisense drug adoption as rare disease diagnosis improves. Growth will depend on reimbursement, clinical guidelines, physician confidence and safety monitoring.

India

India is an expanding market supported by a large infectious disease burden, vaccine manufacturing strength, rising genomic medicine interest and growing private hospital networks. Vaccines remain the primary near-term opportunity due to public health programs and potential technology transfer. Drugs will grow more gradually as RNA interference and antisense therapies become available through tertiary hospitals and specialty centers. Research Institutes will play an important role in local RNA platform development, delivery science and cost-efficient manufacturing models. Growth will depend on affordability, regulatory clarity, domestic partnerships, clinical trials and public-private investment.

South Korea

South Korea represents a high-value RNA therapeutics market supported by advanced biomanufacturing, hospital infrastructure, clinical trial capacity and digital health integration. Vaccines, RNA interference and RNA antisense therapies can benefit from strong specialist care and government support for biotechnology innovation. Hospitals and Specialty Centers are well positioned to adopt rare disease and infectious disease products as evidence expands. Research Institutes and domestic biotechnology firms are expected to strengthen platform development. Growth will depend on reimbursement, clinical validation, regional partnerships, manufacturing capacity and export-oriented RNA technology investment.

Australia and New Zealand

Australia and New Zealand represent mature markets supported by strong regulatory systems, advanced clinical research and structured reimbursement pathways. Australia’s approval of Moderna’s mNEXSPIKE XBB.1.5 mRNA vaccine highlights continued regulatory activity for RNA vaccine products. Hospitals and Specialty Centers will remain important for RNA-based Drugs, especially in rare genetic disease treatment. Research Institutes support platform development, clinical trials and translational medicine. Growth will remain steady as reimbursement decisions, safety data and clinical guidelines determine access to premium RNA therapies.

Southeast Asia

Southeast Asia offers long-term growth potential as public health systems, private hospitals, clinical research networks and specialty care access expand. Singapore is likely to lead early adoption due to stronger regulatory and research infrastructure, while Thailand, Malaysia, Indonesia, Vietnam and the Philippines will adopt RNA-based therapeutics at different speeds. Vaccines will remain the strongest near-term opportunity due to infectious disease prevention and preparedness. Drugs will expand gradually through specialty hospitals and rare disease programs. Growth will depend on affordability, cold-chain systems, payer coverage, physician awareness and regional procurement.

Report Attribute Details

Asia Pacific RNA-based Therapeutics Market Segmentations

By Product

• Vaccines
• Drugs

By Type

• RNA interference
• RNA antisense

By Indication

• Infectious Diseases
• Rare Genetics Disease
• Others

By End Use

• Hospital
• Specialty Centers
• Research Institutes

Key Players

• Moderna, Inc.
• Pfizer, Inc.
• Alnylam Pharmaceuticals, Inc.
• Novartis AG
• Ionis Pharmaceuticals, Inc.
• Sanofi
• Sarepta Therapeutics, Inc.
• Orna Therapeutics
• Curevac SE
• Sirnaomics

Recent Developments

• In May 2025, Moderna Japan received marketing authorization for mRESVIA, an RSV mRNA vaccine for adults aged 60 and older in Japan.
• In August 2025, Pfizer and BioNTech received Japan approval for LP.8.1-adapted Comirnaty COVID-19 RNA vaccine formulations for the 2025-2026 season.
• In December 2025, Australia’s TGA approved Moderna’s mNEXSPIKE XBB.1.5 mRNA COVID-19 vaccine for active immunization in individuals aged 12 years and older.
• In 2025, Alnylam reported full-year AMVUTTRA revenue of USD 2.314 billion and ONPATTRO revenue of USD 173 million, reflecting strong commercial growth for RNA interference therapeutics.

Report Coverage

The research report offers an in-depth analysis based on product, type, indication, end use and geography. It details leading market players, providing an overview of their business positioning, RNA vaccine platforms, RNA interference drugs, RNA antisense therapies, rare genetic disease portfolios, infectious disease programs, clinical research activity and strategic relevance in the Asia Pacific RNA-based Therapeutics Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines mRNA vaccine adoption, updated respiratory vaccine approvals, RNAi commercialization, antisense innovation, rare disease treatment, research institute activity and hospital-led specialty access as major factors shaping market development. The report assesses the impact of delivery limitations, high therapy cost, reimbursement barriers, regulatory complexity, cold-chain requirements and manufacturing constraints on market growth. It provides strategic recommendations for RNA therapeutics companies, vaccine developers, hospitals, specialty centers, research institutes, payers, investors and new entrants seeking to navigate Asia Pacific’s RNA-based therapeutics ecosystem.

Future Outlook

• Demand for RNA-based therapeutics will continue to rise as infectious disease preparedness and rare genetic disease treatment expand across Asia Pacific.
• Vaccines will remain a leading product segment due to recurring COVID-19 updates, RSV prevention and future respiratory vaccine development.
• Drugs will gain share as RNA interference and RNA antisense therapies expand in rare disease and specialty medicine.
• RNA interference will gain momentum through stronger commercial performance and broader gene-silencing pipelines.
• RNA antisense will remain important for rare genetic disease, neurology and transcript-modifying treatment strategies.
• Infectious Diseases will remain the largest near-term indication due to vaccine demand and respiratory disease preparedness.
• Rare Genetics Disease will grow as genetic testing, orphan drug access and specialty care networks improve.
• Hospitals will remain the leading end-use segment because RNA therapies require specialist prescribing and monitoring.
• Research Institutes will strengthen platform innovation in RNA chemistry, delivery systems and translational development.
• Competition will increase as companies compete on delivery technology, clinical evidence, regulatory speed, manufacturing scalability, pricing and regional partnerships.